CAR T-cell therapy for large B-cell lymphoma after prior CAR T treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma.
- Your lymphoma must have come back or not responded after at least two prior treatments, including a standard CAR T-cell therapy (like Yescarta or Kymriah) that you received at least 3 months ago.
- You must have measurable disease, meaning the lymphoma can be seen on scans.
- You cannot have had a stem cell transplant from a donor (allogeneic transplant) before.
- You cannot have had a stem cell transplant using your own cells (autologous) within 12 weeks of the study's cell collection.
- You cannot have received any other experimental CAR T-cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.